LUCD
Lucid Diagnostics Inc.
There isn't enough reported data to score LUCD yet.
LUCD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
LUCD's revenue is currently stable, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LUCD PE Valuation
LUCD has no meaningful PE right now: it lost money over the past year.
LUCD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LUCD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LUCD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$0.87 | +$0.26 |
| Q2 2025 | -$1.02 | +$0.20 |
| Q1 2025 | -$1.17 | +$0.09 |
| Q4 2024 | -$1.05 | +$0.21 |
| Q3 2024 | -$1.13 | +$0.29 |
| Q2 2024 | -$1.22 | +$0.25 |
| Q1 2024 | -$1.26 | +$0.35 |
| Q4 2023 | -$1.26 | +$0.30 |
LUCD is still losing money, but less than at its worst: $0.87 per share over the past year, against $1.61 at its worst in early 2023.
LUCD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2M | -0.7% |
| Q2 2026 | $1.5M | +27% |
| Q1 2026 | $1.3M | +52% |
| Q4 2025 | $1.5M | +26% |
| Q3 2025 | $1.2M | +3.3% |
| Q2 2025 | $1.2M | +19% |
| Q1 2025 | $828K | -17% |
| Q4 2024 | $1.2M | +15% |
LUCD's revenue is growing: $1M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1020% | -49 points |
| Q2 2026 | -868% | +110 points |
| Q1 2026 | -964% | +544 points |
| Q4 2025 | -932% | +102 points |
| Q3 2025 | -971% | +27 points |
| Q2 2025 | -979% | +168 points |
| Q1 2025 | -1508% | -430 points |
| Q4 2024 | -1034% | +67 points |
LUCD's operating margin was −1020% last quarter, down 49 points from the same quarter a year ago.
LUCD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.6M | -$4.7M |
| Q2 2026 | -$11.3M | -$769K |
| Q1 2026 | -$12.3M | +$149K |
| Q3 2025 | -$10.9M | -$718K |
| Q2 2025 | -$10.5M | +$933K |
| Q1 2025 | -$12.5M | +$147K |
| Q1 2024 | -$12.6M | -$5.6M |
| Q1 2023 | -$7.1M | -$1.1M |
LUCD has burned cash in almost every quarter: −$50M over the past year, against −$43M the year before.
LUCD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.3% | +7.8M shares |
| 1 year | +93% | +92M shares |
| 3 years | +366% | +150M shares |
| 5 years | +416% | +154M shares |
| Available history | +416% | +154M shares |
LUCD has 191M diluted shares, up 93% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LUCD Net Leverage
LUCD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LUCD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.4 | Oversold |
| Stochastic | 14.0 | Oversold |
LUCD's weekly RSI is 24 (oversold) and its Stochastic is 14 (oversold).
LUCD PE vs Healthcare Sector
LUCD has no meaningful PE right now: it lost money over the past year.
LUCD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.52 | 19% below |
| 20 week MA | $0.77 | 45% below |
| 50 week MA | $1.00 | 58% below |
| 100 week MA | $1.09 | 61% below |
| 200 week MA | $1.14 | 63% below |
LUCD is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
LUCD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.35 | $4.92 | -47% |
| 2022 | $4.92 | $1.40 | -72% |
| 2023 | $1.40 | $1.41 | +0.7% |
| 2024 | $1.41 | $0.79 | -44% |
| 2025 | $0.79 | $1.09 | +38% |
| 2026 YTD | $1.09 | $0.42 | -61% |
LUCD has finished lower in three of the last five years. It's down 61% so far in 2026.